Anti-diabetic drug pioglitazone lowers cardiovascular risk in diabetics with kidney disease A new research confirms that chronic kidney disease increases the already-high threat of serious cardiovascular events in diabetics with harm to the large blood vessels and suggests that treatment with the anti-diabetic drug pioglitazone can help to lower this risk, the January Journal of the American Culture of Nephrology reports. ‘The data confirm that chronic kidney disease can be an independent risk factor for main adverse cardiovascular occasions and death, actually amongst an extremely high-risk population of patients with diabetes and pre-existing macrovascular disease,’ comments Dr breath shortening .
The Company has concluded a Phase I trial in patients with prostate cancer also. .. Antigen Express provides revise on ongoing AE37 Phase 2 trial in breasts cancer Generex Biotechnology Corporation ( announced today that the business’s wholly-owned subsidiary Antigen Express, Inc. ( presented an update of the ongoing Stage 2 trial with an off-the-shelf immunotherapeutic tumor vaccine, AE37, in patients with breast cancer at Cambridge Healthtech Institute’s 6th Annual ImVacS: The Immunotherapeutics and Vaccine Summit held August 16-18, 2011 in Cambridge, MA. Related StoriesNew results reveal association between colorectal tumor and melanoma drug treatmentCornell biomedical engineers develop 'super organic killer cells' to destroy tumor cells in lymph nodesFDA grants accelerated authorization for Tagrisso to take care of patients with advanced NSCLCIn a presentation titled Clinical Development of a Modified, Self-Potentiating HER2 Peptide Vaccine in Prostate and Breasts Cancer Patients, Dr.